ASCO 2019

The American Society of Oncology (ASCO) 2019 Annual Meeting was held in Chicago, IL, from 31 May – 4 June. A world-renowned faculty discussed state-of-the-art treatment modalities, ongoing controversies in the field, and the latest data.

1:34
Myeloma: pomalidomide, bortezomib and dexamethasone
Paul Richardson
3:31
ZUMA-1 trial observations
Paolo Strati
1:29
Further progression for CAR T-cell therapy?
Paolo Strati
2:28
CITADEL-101 study- Parsaclisib in R/R B-cell malignancies
Tycel Phillips
3:30
Isatuximab: an important new option in R/R MM
Paul Richardson
3:28
Lymphoma: pre-treatment PET scans
Paolo Strati
3:27
Selinexor: an underappreciated MM development
Paul Richardson
1:22
Pre-treatment PET scans
Paolo Strati
0:52
ASCO 2019: CAR-T trial highlights
Nirav Niranjan Shah
1:46
IVLBCL: a retrospective study
Tycel Phillips
2:22
CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma
Nirav Niranjan Shah
1:58
Should we transplant or not in frontline therapy for MCL?
Tycel Phillips
0:42
CAR need an upgrade?
Nirav Niranjan Shah
1:24
Multiple myeloma treatment strategies: what does the future hold?
Enrique Ocio
2:24
Drug trial updates in multiple myeloma and SMM
Enrique Ocio
2:15
Waldenström’s macroglobulinemia: what options are available?
Jithma Abeykoon
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals